Risankizumab Study Investigates T-Cell Autoimmunity in Moderate to Severe Psoriasis
Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
Background
Psoriasis is a chronic autoimmune disease characterized by inflamed, scaly skin patches, driven by an overactive immune system. Interleukin-23 (IL-23), a key cytokine (signaling protein) that promotes inflammation, plays a central role in its pathogenesis, making IL-23 inhibitors like Risankizumab effective treatments. This study aims to understand how Risankizumab treatment impacts the specific autoreactive T-cells (targeting LL37 and ADAMTSL5) believed to contribute to psoriasis.